Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Rating) saw a significant increase in short interest in the month of December. As of December 30th, there was short interest totalling 224,600 shares, an increase of 15.6% from the December 15th total of 194,300 shares. Approximately 6.2% of the company's shares are sold short. Based on an average trading volume of 42,500 shares, the days-to-cover ratio is currently 5.3 days.

Insider Buying and Selling

In other Greenwich LifeSciences news, CEO Snehal Patel bought 2,000 shares of the firm's stock in a transaction that occurred on Friday, December 9th. The stock was acquired at an average price of $13.11 per share, with a total value of $26,220.00. Following the completion of the purchase, the chief executive officer now directly owns 2,724,886 shares of the company's stock, valued at approximately $35,723,255.46. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have purchased a total of 8,250 shares of company stock valued at $104,275 over the last ninety days. 52.14% of the stock is owned by company insiders.

Institutional Investors Weigh In On Greenwich LifeSciences

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in Greenwich LifeSciences by 150.2% during the first quarter. Vanguard Group Inc. now owns 375,200 shares of the company's stock worth $7,362,000 after purchasing an additional 225,213 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of Greenwich LifeSciences in the 2nd quarter valued at approximately $891,000. Millennium Management LLC bought a new stake in shares of Greenwich LifeSciences during the 2nd quarter valued at $765,000. Occudo Quantitative Strategies LP bought a new stake in Greenwich LifeSciences during the second quarter worth about $199,000. Finally, Pura Vida Investments LLC bought a new stake in shares of Greenwich LifeSciences in the 3rd quarter worth approximately $179,000. 6.18% of the stock is currently owned by institutional investors.

Greenwich LifeSciences Trading Up 2.1 %

Greenwich LifeSciences (NASDAQ:GLSI – Get Rating) last posted its quarterly earnings results on Monday, November 14th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.01. As a group, equities analysts anticipate that Greenwich LifeSciences will post -0.57 EPS for the current fiscal year.

About Greenwich LifeSciences

(Get Rating)

Greenwich LifeSciences, Inc, a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.

Further Reading

• Get a free copy of the StockNews.com research report on Greenwich LifeSciences (GLSI)
• Is Wayfair Still Way Cheap For Investors?
• When Does Pfizer Become A Bargain?
• Tractor Supply Company Shares Could be Headed to New Highs
• Is Canadian Solar Too Hot to Handle?
• UiPath is the Blue-Collar AI Platform to Watch in 2023

Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.